P21 PeptideNeurotrophic PeptideSafety Rating 6/10

TypeCNTF-derived neurotrophic peptide
CASNot standardized
MWNot well characterized publicly
AAsNot well characterized publicly
Primary research areaNeurotrophic research

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose rangeLimited clinical data; mouse studies used 50 nmol/daysource ↗
AdministrationSubcutaneous (research) or intraperitoneal (mice)
Half-lifeNot well characterized in humans
Safety6/10 · Not FDA-approved
NCAA D1Not listed

Price Comparison

Compare vendors · per 10mg

4 vendors competing

VendorPrice$ / mgUpdated
PureRawzBest $/mgCOA ✓ · 3P$62.48$6.25May 14, 2026Buy →
SomaChemsCOA ✓ · 3P$67.99$84.99−20% · code PEPTIDEPRICES$6.80May 14, 2026Buy →
Modern AminosCOA ✓ · 3P$98.00$9.80May 14, 2026Buy →
Core PeptidesCOA ✓ · 3P$116.00$23.20Apr 16, 2026Buy →

Overview

About P21 Peptide

Mechanism of action

Tetrapeptide derived from ciliary neurotrophic factor (CNTF); activates gp130 signaling; promotes BDNF expression and neurogenesis; enhances synaptic plasticity; reduces Alzheimer's tau pathology.

Safety profile

Very limited human data. Generally well-tolerated in animal studies. · BDNF mimetic; limited data but no proven harms; theoretical mechanism favorable

Storage

Stability & handling

❄️Lyophilized (powder)−20°Clong-term stable
💉Reconstituted2–8°Cwithin 30 days
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on P21 Peptide

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • p21/CDKN1A is the primary effector of p53-driven cell cycle arrest and a central mediator of cellular senescence; it can function as both a classical tumor suppressor (arresting damaged cells) and, paradoxically, as a proto-oncogenic survival factor in established tumors, with its role determined by cellular context, subcellular localization, and interaction partners.
  • A 2021 Science study found that p21-activated cells produce a bioactive secretome (PASP, including CXCL14) that recruits macrophages for immunosurveillance of stressed and precancerous cells — a tumor-suppressive mechanism; persistent p21 expression triggers M1 macrophage polarization and cytotoxic T-cell recruitment, placing stressed cells under immune clearance.

7 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch